The first Calithera Biosciences trade was made in Q3 2015.
Since then Ken Griffin bought shares 31 more times and sold shares on 25 occasions. The investor completely sold their stake between Q3 2022 and Q1 2023.
Avg closing price
Price range
Sold -199 Thousand shares
Q1 2023
Avg closing price
$0.39
Price range
$0.04
-
$3.62
Sold 0.2% shares (-421 shares)
Q4 2022
Avg closing price
$2.39
Price range
$1.36
-
$3.26
Sold 5.6% shares (-11.8 Thousand shares)
Q3 2022
Avg closing price
$3.42
Price range
$2.42
-
$4.88
Increased shares by 5.9% (+11.7 Thousand shares)
Q2 2022
Avg closing price
$4.64
Price range
$2.41
-
$7.34
Increased shares by 13.3% (+23.5 Thousand shares)
Q1 2022
Avg closing price
$10.22
Price range
$7.78
-
$13.56
Increased shares by 233.9% (+123 Thousand shares)
Q4 2021
Avg closing price
$25.13
Price range
$12.49
-
$42.40
Increased shares by 3751.4% (+51.4 Thousand shares)
Q3 2021
Avg closing price
$43.14
Price range
$37.20
-
$49.00
New holding (+1.37 Thousand shares)
Q2 2021
Avg closing price
$43.94
Price range
$39.20
-
$50.00
Sold -731 shares
Q1 2021
Avg closing price
$58.20
Price range
$47.80
-
$73.20
New holding (+731 shares)
Q3 2020
Avg closing price
$87.25
Price range
$67.20
-
$109.80
Sold -2.42 Thousand shares
Q2 2020
Avg closing price
$118.78
Price range
$82.20
-
$157.00
Increased shares by 51.6% (+824 shares)
Q1 2020
Avg closing price
$119.13
Price range
$64.20
-
$156.00
Increased shares by 27.6% (+346 shares)
Q4 2019
Avg closing price
$75.21
Price range
$50.40
-
$123.40
Sold 88.3% shares (-9.47 Thousand shares)
Q3 2019
Avg closing price
$80.05
Price range
$61.80
-
$89.60
Increased shares by 463.8% (+8.82 Thousand shares)
Q2 2019
Avg closing price
$113.50
Price range
$74.20
-
$135.00
Sold 31.5% shares (-875 shares)
Q1 2019
Avg closing price
$105.05
Price range
$81.60
-
$134.80
Sold 54.6% shares (-3.34 Thousand shares)
Q4 2018
Avg closing price
$98.61
Price range
$72.40
-
$124.80
Increased shares by 28.5% (+1.36 Thousand shares)
Q3 2018
Avg closing price
$95.21
Price range
$82.00
-
$109.00
Increased shares by 29.2% (+1.08 Thousand shares)
Q2 2018